Announcement no. 01/2025 | 4 February 2025
1
2024/25
Interim financial results, Q1 2024/25
1 October 2024 - 31 December 2024
Coloplast delivered 8% organic growth and an EBIT margin
1
of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6%
and included negative impact from the divestment of Skin Care and currencies.
• Organic growth rates by business area: Ostomy Care 7%, Continence Care 7%, Voice and Respiratory Care 11%, Advanced Wound
Care 12% and Interventional Urology 1%.
• Growth in Chronic Care was driven by solid contributions from Europe and the US, while growth in Emerging markets was
impacted by a high baseline last year. In Continence Care, Luja™ was the main contributor to growth.
• Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy.
• Advanced Wound Dressings delivered 6% growth in the quarter, driven by Europe. In December 2024, Coloplast divested its Skin
Care portfolio to simplify business operations and improve profitability in Advanced Wound Care.
• Kerecis delivered 32% growth, reflecting continued market share gains, and an EBIT margin ex. PPA amortisation of 12%, as
expected. Kerecis was included on the list for Diabetic Foot Ulcers on the final Local Coverage Determination policy announced on
14 November 2024. The implementation date for the final policy has been updated to 13 April 2025.
• Growth in Interventional Urology was negatively impacted by a voluntary product recall in Bladder Health and Surgery (around DKK
25 million in Q1), partly offset by solid performance in Endourology. The product recall is expected to impact Q2 with around DKK 15
million. Sales of the affected products will resume during February.
• EBIT
1
was DKK 1,912 million, a 5% increase from last year. The EBIT margin
1,2
was 27% against 28% last year and includes a higher
level of commercial and logistics costs, including around DKK 20 million extraordinary costs related to the establishment of the US
distribution centre, and negative impact from currencies.
• The ordinary tax rate in Q1 was 22%, while the effective tax rate amounted to 41% due to an extraordinary expense related to
transfer of Kerecis’s Intellectual Property (IP) from Iceland to Denmark to ensure consistency with Coloplast’s tax model. The IP
transfer will result in a tax payment in Iceland impacting cash flows in FY 2026/27 at the earliest, to be fully offset by reduced tax
payments in Denmark starting in FY 2024/25.
• Adjusted
3
net profit before special items was DKK 1,438 million, a DKK 214 million increase from last year. Adjusted
3
diluted earnings
per share (EPS) before special items increased by 17% to DKK 6.38. Including the impact from the Kerecis IP transfer, the net profit
before special items was DKK 1,102 million, while EPS before special items decreased by 10% to DKK 4.89.
• Adjusted
3
ROIC after tax before special items was 15%, on par with last year. Including the impact from the Kerecis IP transfer, ROIC
after tax and before special items was 11%.
FY 2024/25 guidance on organic growth of 8-9% and on EBIT margin before special items of around 28% unchanged.
• Organic growth assumes continued good momentum, around 1%-point contribution from Kerecis and improvement in growth in
Interventional Urology in H2.
• Reported growth in DKK is now expected around 7%, from previously 8-9%, and includes around 1.5%-points negative impact from
the Skin Care divestment (10 months) and neutral impact from currencies.
• The reported EBIT margin before special items
4
assumes benefit from lower inflationary pressure on input costs and benefit from
profitability improvement initiatives in Advanced Wound Care, around 100 basis points dilution from Kerecis and limited positive
impact from currencies.
• Capital expenditures are still expected to be around DKK 1.4 billion. The ordinary tax rate is still expected around 22%, however,
the effective tax rate is now expected to be around 40% due to the extraordinary impact from the Kerecis IP transfer. The long-
term tax rate expectations of around 23% are unchanged.
“We delivered a Q1 as expected with 8% organic growth and an EBIT margin of 27%. I want to highlight a good start to the year in
Chronic Care in Europe and the US, including a significant contribution to growth from our new intermittent catheter platform Luja™,
1. before special items expenses of DKK 74 million in Q1 2024/25. 2. before special items expenses of DKK 15 million in Q1 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer.
4. FY 2024/25 special items expected to be an expense of around DKK 130 million.
Conference call
Coloplast will host a conference call on Tuesday, 4 February 2025 at 11.00 CET. The call is expected to last about one hour.
To actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here
Access the conference call webcast directly here: Coloplast - Q1 2024/25 Earnings release conference call
Announcement no. 01/2025 | 4 February 2025
2
offsetting softer numbers in Emerging Markets as well as our Interventional Urology business this quarter. Finally, I am pleased to see
that our two recent acquisitions, Atos Medical and Kerecis, continue to deliver double-digit growth, raising the standard of care for
many more people living with intimate healthcare needs,” says President & CEO Kristian Villumsen.
Announcement no. 01/2025 | 4 February 2025
3
Financial highlights and key ratios
1 October 2024 – 31 December 2024, unaudited
¹⁾ The FTE definition has been reassessed during 2023/24 and the comparison figures have been adjusted.
²⁾ Before special items. After special items, ROIC before tax was 18% (2023/24: 18%), and ROIC after tax was 11% (2023/24: 15%).
Consolidated
2024/25
2023/24
Q1
Q1
Change
Income statement, DKK million
Revenue
7,026
6,606
6%
Research and development costs
-219
-233
-6%
Operating profit before interest, tax, depr. and amort. (EBITDA) before special items
2,240
2,130
5%
Operating profit before interest, taxes and amortization (EBITA) before special items
2,030
1,932
5%
Operating profit (EBIT) before special items
1,912
1,822
5%
Special items
-74
-15
N/A
Operating profit (EBIT)
1,838
1,807
2%
Net financial income and expenses
-69
-253
-73%
Profit before tax
1,769
1,554
14%
Net profit for the period
1,044
1,212
-14%
Revenue growth, %
Period growth in revenue, %
6
8
Growth break down:
Organic growth, %
8
8
Currency effect, %
-1
-4
Acquired operations, %
-
4
Divested Operations, %
-1
-
Balance sheet, DKK million
Total assets
48,338
48,591
-1%
Capital invested
40,267
37,140
8%
Net interest-bearing debt (NIBD)
23,852
20,719
15%
Equity end of period
15,461
15,125
2%
Cash flow and investments, DKK million
Cash flows from operating activities
2,007
1,788
12%
Cash flows from investing activities
-133
-267
-50%
Investments in property, plant and equipment, gross
-278
-236
18%
Free cash flow
1,874
1,521
23%
Cash flows from financing activities
-1,761
-1,477
19%
Key ratios
Average number of employees, FTEs¹⁾
Operating margin (EBIT margin) before special items, %
27
28
Operating margin (EBIT margin), %
26
27
Operating margin before interest, tax, depr. and amort., (EBITDA margin), %
31
32
Gearing ratio, NIBD/EBITDA before special items
2.7
2.4
Return on average invested capital before tax (ROIC), %²⁾
19
20
Return on average invested capital after tax (ROIC), %²⁾
11
15
Return on equity, %
25
30
Equity ratio, %
32
31
Net asset value per outstanding share, DKK
69
67
3%
Share data
Share price, DKK
786
772
2%
Share price/net asset value per share
11.5
11.5
0%
Average number of outstanding shares, millions
225.3
224.5
0%
PE, price/earnings ratio
42.5
35.7
19%
Earnings per share (EPS), diluted
4.63
5.39
-14%
Earnings per share (EPS) before special items, diluted
4.89
5.45
-10%
Free cash flow per share
7.2
6.8
6%
Announcement no. 01/2025 | 4 February 2025
4
Sales performance
Organic growth in Q1 was 8%. Reported revenue in DKK grew 6% to DKK 7,026 million. Divested operations contributed -1% to
reported revenue, related mostly to the divestment of Skin Care in December 2024, as well as negative impact from the divestment of
MC Europe in Voice and Respiratory Care in December 2023. Exchange rate developments decreased revenue by 1%, mainly related to
the depreciation of a basket of Emerging markets currencies and JPY against the DKK.
Sales performance by business areas*
DKK million
Growth composition (3 mths)
2024/25
(3 mths)
2023/24
(3 mths)
Organic
growth
Divested
operations
Exchange
rates
Reported
growth
Ostomy Care
2,537
2,382
7%
-
-1%
7%
Continence Care
2,208
2,067
7%
-
0%
7%
Voice and Respiratory Care
557
508
11%
-2%
0%
10%
Advanced Wound Care
1,011
946
12%
-4%
-1%
7%
Interventional Urology
713
703
1%
-
0%
1%
Revenue
7,026
6,606
8%
-1%
-1%
6%
Sales performance by region*
DKK million
Growth composition (3 mths)
2024/25
(3 mths)
2023/24
(3 mths)
Organic
growth
Divested
operations
Exchange
rates
Reported
growth
European markets
3,808
3,565
6%
0%
1%
7%
Other developed markets
2,079
1,928
11%
-2%
-1%
8%
Emerging markets
1,139
1,113
8%
0%
-6%
2%
Revenue
7,026
6,606
8%
-1%
-1%
6%
* The sum of organic growth, divested operations and exchange rates might not match total reported growth due to rounding of numbers.
Announcement no. 01/2025 | 4 February 2025
5
Ostomy Care
Ostomy Care generated 7% organic sales
growth for the first quarter of 2024/25,
with reported revenue in DKK growing by
7% to DKK 2,537 million.
The SenSura® Mio portfolio was the main
contributor to growth, with good
performance across the product range
which includes Convex, Concave and Flat
products. At the product level, SenSura
Mio Convex was the main growth
contributor, driven by Europe, particularly
the UK and Germany, and the US. The
SenSura and Assura/Alterna® portfolios
contributed to growth in Emerging
markets, where they are being actively
promoted. The Brava® range of
supporting products also made a solid
contribution to growth, with broad-based
contribution across all regions, most
notably the US.
During 2024, the SenSura Mio portfolio
was strengthened with three new product
launches, most notably the SenSura Mio
black bags which are available in 12
markets and off to a good start.
From a geographical perspective, growth
was driven by solid contributions from
Europe, driven by the UK and Germany,
and the US. The US posted solid growth in
Q1 which includes benefit from a lower
baseline last year. Growth in Emerging
markets was impacted by a high baseline
last year. China delivered mid-single digit
growth, in line with expectations.
Continence Care
Continence Care generated 7% organic
sales growth for the first quarter of
2024/25, with reported revenue in DKK
growing by 7% to DKK 2,208 million.
Luja™, Coloplast’s new intermittent
catheter with a Micro-hole Zone
Technology, was the main growth
contributor in the quarter, driven by the
male catheter in the UK and Germany.
Luja for women also performed well. The
rollout of Luja for women is ongoing, and
the product is available in nine markets as
of January 2025. The SpeediCath® ready-
to-use hydrophilic intermittent catheters
also contributed to growth in the quarter.
Sales growth in the SpeediCath portfolio
was broad-based across standard,
compact, and flexible catheters, driven by
the US and Emerging markets, particularly
LATAM.
Bowel Care and Collecting Devices both
contributed to growth in the quarter. In
Bowel Care, growth was driven by a solid
contribution from Peristeen® Plus in
Europe. Peristeen Light*, a low-volume
transanal irrigation device, has been
launched in six markets.
From a geographical perspective, growth
was driven by Europe, with solid
contributions from the UK and France,
and the US. Growth in Emerging markets
was impacted by a high baseline last year.
Markets with recent reimbursement
openings continued to perform well and
posted double-digit growth.
*Medical Devices for which CE-mark has been affixed. Product availability is subject to the regulatory process of individual
countries and is not guaranteed. Currently not available in the US.
Ostomy Care
Organic growth
Reported growth
Continence
Care
Organic growth
Reported growth
7%
8%
Q1 2024/25 Q1 2023/24
7%
5%
Q1 2024/25 Q1 2023/24
7%
8%
Q1 2024/25 Q1 2023/24
7%
4%
Q1 2024/25 Q1 2023/24
Announcement no. 01/2025 | 4 February 2025
6
Voice and Respiratory
Care
Voice and Respiratory Care generated
11% organic sales growth for the first
quarter of 2024/25, driven by double-digit
growth in both Laryngectomy and
Tracheostomy. Reported revenue in DKK
grew by 10% to DKK 557 million and
included 2%-points negative impact from
product rationalization related to the
divestment of MC Europe, a business that
sold non-core products, in December
2023.
In Laryngectomy, growth in the quarter
was driven by an increase in patients
served in existing and new markets and an
increase in patient value driven by the
Provox® Life™ portfolio, Atos Medical’s
product line launched in 2019 which
allows for a personalised regime.
In Tracheostomy, growth was driven by
solid demand and an increase in the
number of patients served.
From a geographical perspective, growth
was broad-based, driven by Europe and
the US. Markets with recent
reimbursement openings, such as Poland,
made a solid contribution to growth and
grew double-digit.
Advanced Wound Care
Advanced Wound Care generated 12%
organic sales growth for the first quarter
of 2024/25. Reported revenue was DKK
1,011 million, a 7% increase from last year
which includes 4%-points negative impact
from the divestment of the Skin Care
business.
Advanced Wound Dressings in isolation
delivered 6% organic growth in the
quarter. Biatain® Fiber was the main
contributor to growth, followed by Biatain
Silicone. Biatain Superabsorber, a soft and
non-adhesive dressing that can manage
high volumes of exudate, was launched in
October 2024 in Europe and is off to a
good start with solid contribution to
growth. From a geographical perspective,
growth was driven by Europe, in particular
Germany.
Revenue from Kerecis amounted to DKK
303 million in Q1, with growth of 32%
from last year and continued market
share gains, in line with expectations.
Growth was broad-based, with solid
contributions from both the out-patient
and in-patient settings. Impact from the
final Local Coverage Determination policy
has so far been immaterial. The
implementation date of the policy has
been updated to 13 April 2025, from
previously 12 February 2025. From a
geographical perspective, both sales and
growth were derived from the US.
In December 2024, Coloplast announced
the divestment of its Skin Care portfolio,
part of a strategic initiative to simplify
business operations and improve
profitability in Advanced Wound Care. The
divestment will reduce reported revenue
for FY 2024/25 with around DKK 350
million (10 months impact), or around -
1.5%-points impact on reported revenue
growth, and will have a positive impact on
the group EBIT margin.
Announcement no. 01/2025 | 4 February 2025
7
Voice and
Respiratory
Care
Organic growth
Reported growth
Advanced
Wound Care
Organic growth
Reported growth
11%
7%
Q1 2024/25 Q1 2023/24
10%
6%
Q1 2024/25 Q1 2023/24
12%
9%
Q1 2024/25 Q1 2023/24
7%
40%
Announcement no. 01/2025 | 4 February 2025
8
Interventional Urology
Interventional Urology generated 1%
organic sales growth for the first quarter
of 2024/25, with reported revenue in DKK
growing by 1% to DKK 713 million.
Growth in the quarter was negatively
impacted by a voluntary product recall in
the Bladder Health and Surgery segment
of around DKK 25 million in Q1. The
product recall was initiated in December
2024 due to a possible sterility issue
related to the packaging of the products,
discovered during internal testing. The full
impact of the product recall is expected to
be around DKK 40 million, with continued
negative impact in Q2. The packaging of
the affected products has been updated
and sales of the products will resume
during February. The majority of lost
revenues in H1 2024/25 are expected to
be recovered in H2.
The impact from the product recall in Q1
was partly offset by solid contribution
from the Endourology segment, primarily
driven by Europe and Thulium Fiber Laser
Drive, Coloplast’s laser equipment
launched in FY 2022/23. The Men’s Health
business in the US also contributed to
growth, driven by the Titan® penile
implants, while the Women’s Health
business had a neutral impact on growth.
From a geographical perspective, the US
was the main growth contributor. Europe
made a negative contribution to growth
due to the abovementioned product
recall.
Interventional
Urology
Organic growth
Reported growth
1%
5%
Q1 2024/25 Q1 2023/24
1%
2%
Q1 2024/25 Q1 2023/24
Announcement no. 01/2025 | 4 February 2025
9
Earnings
Gross profit
Gross profit was DKK 4,750 million,
compared to DKK 4,504 million last year,
corresponding to a gross margin of 68%,
on par with last year. The gross margin
was positively impacted by a favourable
development in input costs, price
increases, and country and product mix.
The above-mentioned positive drivers
were partly offset by ramp-up costs in
Costa Rica and Portugal. Currencies also
had a negative impact on the gross
margin.
Costs
Operating expenses amounted to DKK
2,838 million, a DKK 156 million increase
(6%) from last year.
Distribution costs amounted to DKK 2,329
million, a DKK 199 million (9%) increase
from DKK 2,130 million last year. The
higher distribution costs reflect continued
commercial investments in Kerecis, as well
as increased sales activities across
business areas. Distribution costs were
also impacted by extraordinary logistic
costs related to the new US distribution
centre of around DKK 20 million.
Distribution costs amounted to 33% of
revenue compared to 32% last year.
Administrative expenses amounted to
DKK 295 million, a DKK 40 million (12%)
decrease from DKK 335 million last year,
and include positive impact from a high
baseline and synergies from the Atos
Medical integration. Administrative
expenses accounted for 4% of revenue
compared to 5% last year.
The R&D costs were DKK 219 million,
compared to DKK 233 million last year, a
DKK 14 million (6%) decrease. R&D costs
amounted to 3% of revenue, against 4%
last year.
Other operating income and other
operating expenses amounted to a net
income of DKK 5 million against a net
income of DKK 16 million last year.
Operating profit before interest, tax,
depreciation and amortisation (EBITDA)
and before special items
EBITDA before special items amounted to
DKK 2,240 million, a DKK 110 million (5%)
increase from DKK 2,130 million last year.
The EBITDA margin before special items
was 32%, on par with last year.
Operating profit (EBIT) before
special items
EBIT before special items amounted to
DKK 1,912 million, a DKK 90 million (5%)
increase from DKK 1,822 million last year.
The EBIT margin before special items was
27% compared to 28% last year, impacted
by the increase in distribution cost. The
EBIT margin also included negative impact
from currencies of around 40 basis points,
mostly related to the depreciation of a
basket of Emerging markets currencies
and JPY against the DKK.
Special items
During Q1, Coloplast incurred special
items expenses of DKK 74 million, mostly
related to profitability improvement
initiatives in Advanced Wound Care
including the Skin Care divestment,
management restructuring and the
integration of Atos Medical.
Operating profit (EBIT) after
special items
EBIT after special items was DKK 1,838
million, a DKK 31 million (2%) increase
from last year. The EBIT margin after
special items was 26% compared to 27%
last year.
Financial items and tax
Financial items were a net expense of DKK
69 million against a net expense of DKK
253 million last year.
The net expense was impacted by interest
expenses of DKK 195 million compared to
DKK 168 million last year, mostly related
to the financing of the Atos Medical
acquisition. The financial expenses were
partly offset by gains on balance sheet
items of DKK 142 million, mostly driven by
Income statement, DKK million
2024/25
Index
Revenue
7,026
106
Production costs
-2,276
108
Gross profit
4,750
105
Distribution costs
-2,329
109
Administrative expenses
-295
88
Research and development costs
-219
94
Other operating income
13
62
Other operating expenses
-8
160
Operating profit (EBIT) before special items
1,912
105
Special items
-74
N/A
Operating profit (EBIT)
1,838
102
Financial income
200
244
Financial expenses
-269
80
Profit before tax
1,769
114
Tax on profit for the period
-725
212
Net profit for the period
1,044
86
Announcement no. 01/2025 | 4 February 2025
10
the USD, against a loss of DKK 139 last
year which was mostly driven by the ARS.
The ordinary tax expense in Q1 was DKK
389 million, compared to DKK 342 million
last year, with an ordinary tax rate of 22%,
on par with last year. The total tax
expense in Q1 was DKK 725 million,
resulting in an effective tax rate of 41% in
Q1. The total tax expense was impacted
by an extraordinary expense of DKK 336
million related to the transfer of Kerecis’s
Intellectual Property (IP) from Iceland to
Denmark which is consistent with
Coloplast’s principal tax model.
The Kerecis IP transfer will have a similar
quarterly impact on the tax expenses for
the rest of FY 2024/25 as in Q1. As a result
of the Kerecis IP transfer, an extraordinary
tax payment in Iceland impacting cash
flows is expected in FY 2026/27 at the
earliest. The payment will be fully offset
by reduced tax payments in Denmark
starting in FY 2024/25.
Net profit
Adjusted for the impact from the Kerecis
IP transfer, net profit before special items
was DKK 1,438 million, a DKK 214 million
increase from last year. Adjusted diluted
earnings per share (EPS) were DKK 6.38, a
17% increase from last year.
Including the extraordinary impact from
the Kerecis IP transfer, net profit before
special items was 1,102 million, a DKK 122
million decrease from DKK 1,224 million
last year. Diluted earnings per share (EPS)
before special items were DKK 4.89, or a
10% decrease from last year. The
decrease was a result of lower net profit
compared to last year, due to the impact
from the extraordinary tax expense
related to the Kerecis IP transfer.
Net profit after special items was DKK
1,044 million and diluted EPS after special
items were DKK 4.63.
Cash flows and
investments
Cash flows from operating activities
Cash flows from operating activities
amounted to an inflow of DKK 2,007
million, against DKK 1,788 million last year.
The positive development in cash flows
from operating activities was mostly driven
by positive development in working capital,
mostly driven by trade receivables and
inventories, partly offset by an increase in
outgoing interest payments.
Investments
Net investments amounted to DKK 133
million in the first quarter of 2024/25 or
around 2% of revenue, compared with
DKK 267 million last year, and included
positive impact from the divestment of
the core Skin Care product portfolio of
DKK 192 million.
Capital expenditures amounted to DKK
308 million in Q1, or 4% of revenue, on
par with last year.
Free cash flow
As a result, the free cash flow was an
inflow of DKK 1,874 million, compared to
an inflow of DKK 1,521 million in the same
period last year, or a 23% increase.
Excluding benefit from the divestment,
the free cash flow increase in Q1 was 11%.
Capital resources
At 31 December 2024, Coloplast had net
interest-bearing debt of DKK 23,852
million, against DKK 21,841 million at 30
September 2024. The gearing ratio at the
end of the period was 2.7x EBITDA (before
special items).
Coloplast is committed to deleveraging
and bringing the gearing ratio down to
around 2x EBITDA in 2024/25.
Statement of financial
position and equity
Balance sheet
At 31 December 2024, total assets
amounted to DKK 48,338 million, an
increase of DKK 265 million compared to
30 September 2024.
Working capital was 25% of revenue, on
par with 30 September 2024. Inventories
increased by DKK 1 million to DKK 3,673
million, while trade receivables decreased
by DKK 66 million to DKK 4,609 million and
trade payables decreased by DKK 389
million to DKK 1,130 million.
The long-term and FY 2024/25 working
capital-to-sales ratio expectations are
unchanged at around 24%.
Equity
Equity decreased by DKK 2,481 million
compared to 30 September 2024 to DKK
15,461 million. Total comprehensive
income for the period of DKK 1,308
million, effect of sale of treasury shares of
DKK 27 million and share-based
remuneration of DKK 15 million were
offset by payment of dividends of DKK
3,831 million.
Treasury shares
At 31 December 2024, Coloplast’s holding
of treasury shares consisted of 2,833,204
B shares, which was 31,341 less than 30
September 2024. The decrease was due to
exercise of share options.
Return on invested capital (ROIC)
Adjusted for the impact from the Kerecis
IP transfer, ROIC after tax and before
special items was 15%, on par with last
year.
Including the extraordinary impact from
the Kerecis IP transfer, ROIC after tax and
before special items was 11%.
Announcement no. 01/2025 | 4 February 2025
11
Update on sustainability strategy and performance
Priority
Unit
2025 Ambition
Q1
2024/25
Q1
2023/24
Change
FY
2023/24
Improving products and packaging
Recyclable packaging
1)
% of total
90%
-
-
-
74%
Renewable materials in packaging
1)
% of total
80%
-
-
-
68%
Production waste recycling
% of total
75%
78%
75%
3%-p
77%
Reducing emissions
Scope 1 and 2 emissions
% reduction
100% reduction by 2030
2) 4)
28%
13%
15%-p
27%
Renewable energy use
% of total
100%
84%
78%
6%-p
83%
Electric company cars
1)
% of total
100% by 2030
-
-
-
11%
Scope 3 emissions
1)
(by 2030)
% reduction per product
50% reduction by 2030
2) 4)
-
-
-
3%
Business travel by air
1)
% reduction
10% reduction
2)
-
-
-
50%
Goods transported by air
1)
% of total
< 5% of total
-
-
-
2%
Responsible operations
Lost time injury frequency
Parts per million
2.0
1.6
2.8
-1.2
2.1
Code of Conduct training
1)
% of white collars
100%
-
-
-
99%
Female senior leaders (VP+ level)
1)
% of total
40% by 2030
-
-
-
28%
Diverse teams
1)
% share of total teams
75%
-
-
-
56%
Employee satisfaction
1) 3)
Engagement score
Above benchmark
-
-
-
8.1
Improving products and packaging
Production waste recycling increased to
78% in Q1 2024/25, above the 2025
ambition of 75%, driven by Coloplast’s
partnership with a local recycling
manufacturer in Hungary and Costa Rica.
The partnership in Hungary makes it
possible to turn Coloplast’s production
waste into rubber-based composite
flooring and building insulation, while the
partnership in Costa Rica repurposes
Coloplast’s production waste into new
products such as plastic containers and
shoes.
Scope 1 and 2 emissions
The absolute scope 1 and 2 emissions
decreased by 28% in Q1 2023/24,
compared to the base year 2018/19. The
reduction in absolute scope 1 and 2
emissions was positively impacted by the
continued phase-out of natural gas and
energy efficiency improvements.
Renewable energy use increased to 84%
of the total energy use in Q1 2024/25,
compared to 78% in Q1 2023/24, driven
by the aforementioned drivers. Coloplast
has initiated several renewable energy
projects, which are expected to
materialize beyond the current strategy
period.
Responsible operations
The lost time injury (LTI) frequency in Q1
2024/25 was 1.6 ppm, compared to 2.8
ppm in Q1 2023/24, equivalent to a total
of 6 incidents, compared to 17 in Q1
23/24. The improvement was driven by a
positive development in the numbers of
LTIs across all parts of the company.
Coloplast continues to set activities in
motion to address LTIs in order to ensure
a safe working environment for our
employees.
Coloplast ranked one of the most
sustainable MedTech companies
For the fourth year in a row, Coloplast is
recognized among the world’s most
sustainable medical device companies and
ranked as one of the most sustainable
MedTech companies by Corporate Knights
in their 2025 Global 100 Most Sustainable
Corporations of the World list.
5
The inclusion on Corporate Knights’ Global
100 list is a recognition of Coloplast’s
commitment to sustainability and
ambitious initiatives to reduce our
environmental footprint, while continuing
to make life easier for people with
intimate healthcare needs.
2023/24 includes Atos Medical, except for ‘Recyclable packaging’, ‘Renewable materials in packaging’ and ‘Diverse teams’. All figures exclude Kerecis, except for Lost
time injury frequency. 1) Metric will only be reported on a semi-annual or full-year basis. 2) From base year 2018/19. 3) Employee survey conducted annually. Latest
industry benchmark from Q2 2023/24 was 7.8. 4) Target validated by Science-Based Targets initiative (SBTi). 5) For more information on Corporate Knights’ Global
100 list, please refer to: The 100 most sustainable companies of 2025.
Announcement no. 01/2025 | 4 February 2025
12
Other matters
Kerecis included on the list of covered
products for Diabetic Foot Ulcers in the
final LCD policy
On 14 November 2024, the U.S. Centers
for Medicare & Medicaid Services (CMS)
issued a final Local Coverage
Determination (LCD)
1
policy regarding skin
substitute grafts/cellular and tissue-based
products for the treatment of Diabetic
Foot Ulcers (DFUs) and venous leg ulcers
(VLUs) in the Medicare population.
The final LCD policy confirms the
introduction of a technical qualification
and a clinical efficacy qualification,
proposed in a draft LCD policy
2
earlier this
year. The final decision also introduces
two separate lists for covered products for
DFUs and covered products for VLUs. In
addition, the application limit has been
expanded from 4 to 8 and the duration of
treatment has been increased from 12 to
16 weeks in the final policy.
Based on the final evaluation, Kerecis is
included on the final list of covered
products for DFUs, however, Kerecis has
not been included on the covered list for
VLUs. Sales related to VLUs in the out-
patient setting currently represent a low-
single digit portion of the total Kerecis’
sales. Kerecis has an ongoing clinical study
on VLUs
3
and will attempt to get coverage
for VLUs as soon as the study is
completed.
The financial assumptions for Kerecis with
a 3-year CAGR of around 30% until
2025/26 and an EBIT margin of around
20% (ex. PPA amortization) in FY 2025/26
are unchanged. Once the policy is
implemented, we expect loss of sales
related to VLUs in the out-patient
segment. At the same time, given that a
significant number of products are
removed from the covered list for DFUs,
we expect sales growth to accelerate in
this segment, therefore offsetting the loss
of sales related to VLUs.
The implementation date of the final
policy has been updated to 13 April 2025,
from previously 12 February 2025. The
updated timeline is not expected to
impact current trading.
Save the date – Capital Markets Day on 2
September 2025
Coloplast will host a Capital Markets Day
on 2 September 2025 in Denmark. The
event is intended to give institutional
investors and equity analysts an
introduction to the new 5-year strategy
for the company as well as the
opportunity to meet with the broader
Management team. Further details will be
announced in due time.
1. LCD - Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (L39764) 2. Proposed LCD - Skin Substitute Grafts/Cellular and
Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (DL39764) (cms.gov) 3. Study Details | Evaluating Intact Fish Skin Graft and Standard of Care Versus
Standard of Care Alone in Nonhealing Venous Leg Ulcers | ClinicalTrials.gov
Announcement no. 01/2025 | 4 February 2025
13
Long-term financial
guidance
8-10%
Organic growth p.a.
above 30%
EBIT margin beyond 2024/25
(at constant exchange rates)
Key assumptions
Current macroeconomic and industry-
specific trends are continuously
monitored and their potential impact on
our business is evaluated on an ongoing
basis. As such, the financial guidance is
subject to a higher degree of uncertainty.
The addressable market in which
Coloplast operates is expected to continue
growing at 4-5%.
Revenue growth
Organic growth is expected at 8-9% in
constant currencies with the following
assumptions:
a. Growth across business areas and
geographies is expected to be largely
in line with the Strive25 expectations,
with the exception of China Chronic
Care and Interventional Urology
b. China Chronic Care: mid-single digit
growth, with continued impact from
consumer sentiment
c. Interventional Urology: a higher level
of uncertainty due to the product
recall in Bladder Health and Surgery
d. Around 1%-point contribution from
Kerecis to group organic growth
e. No current knowledge of significant
health care reforms; positive pricing
impact is expected. The expectation of
long-term price pressure of up to 1%
annually is unchanged
f. A stable supply and distribution of
products across the company
Reported growth in DKK is expected
around 7% and includes around 1.5%-
points negative impact from the Skin Care
divestment (10 months impact) and
neutral impact from currencies.
EBIT margin
The reported EBIT margin before special
items is expected to be around 28%, with
the following assumptions:
a. Costs of goods sold:
o Tailwind from favourable
development across key input cost
categories as inflationary pressure
has come down
o Negative impact from ramp-up
activities in Costa Rica and Portugal
b. Operating expenses:
o Prudent management of operating
costs, expected to grow below
reported revenue in DKK
o Improvement in profitability in
Advanced Wound Care (ex. Kerecis)
with positive impact on the group
EBIT margin of around 30 basis
points, majority of which related to
the Skin Care divestment
o Incremental investments at the lower
end of the Strive25 guidance (up to
2% of sales in incremental OPEX
investments)
o Kerecis: improvement in profitability,
however, continued negative impact
on the group EBIT margin of around
100 basis points (including around
DKK 100 million in PPA amortisation)
o Limited positive impact from
currencies
Special items of around DKK 130 million,
mostly related to the profitability
improvement initiatives in Advanced
Wound Care, including the Skin Care
divestment, and the Atos Medical
integration.
Capex of DKK 1.4 billion which includes
investments in the new manufacturing
site in Portugal, investments in new
machines for existing and new products,
IT and sustainability investments, as well
as Atos Medical integration capex.
The ordinary tax rate for FY 2024/25 is
still expected to be around 22%, however,
the FY 2024/25 effective tax rate is now
expected to be around 40% due to the
2024/25
Financial
guidance
8-9
%
Organic revenue growth
at constant exchange rates
Around 28
%
Reported EBIT margin
(before special items)
Around 1.4 bn
Capital expenditure in DKK
Around 40
%
Effective tax rate (ordinary
tax rate of around 22%)
Announcement no. 01/2025 | 4 February 2025
14
extraordinary impact from the transfer of
Kerecis’ Intellectual Property.
Coloplast’s long-term expectations for a
tax rate of around 23% are unchanged.
Dividend policy
The Board of Directors intends to
distribute excess liquidity to the
shareholders through dividends and share
buybacks, with a target payout ratio of 60-
80% of net profit.
Forward-looking
statements
The forward-looking statements in this
announcement, including revenue and
earnings guidance, do not constitute a
guarantee of future results and are
subject to risk, uncertainty and
assumptions, the consequences of which
are difficult to predict.
The forward-looking statements are based
on our current expectations, estimates
and assumptions and are provided on the
basis of information available to us at the
present time.
Major fluctuations in the exchange rates
of key currencies, significant changes in
the healthcare sector or major
developments in the global economy may
impact our ability to achieve the defined
long-term targets and meet our guidance.
This may impact our company’s financial
results.
Exchange rate exposure
Our financial guidance for the 2024/25
financial year has been prepared on the
basis of the following assumptions for the
company’s principal currencies:
OVERVIEW OF EXCHANGE RATES FOR KEY
CURRENCIES AGAINST DKK
GBP
USD
HUF
Average exchange
rate 3M 2023/24
856
697
1.92
Average exchange
rate 3M 2024/25
896
699
1.83
Change in average
exchange rates for
2024/25 compared
with the same
period last year
5%
0%
-5%
Average exchange
rate 2023/24¹⁾
872
688
1.92
Spot rate on
31 January 2025
892
717
1.83
Estimated average
exchange rate
2024/25²⁾
893
713
1.83
Change in estimated
average exchange
rates compared with
average exchange
rate 2023/24
2%
4%
-5%
¹⁾ Average exchange rates for 2023/24 are from
1 October 2023 to 30 September 2024.
²⁾ Estimated average exchange rates are
calculated as the average exchange rates for
the first three months combined with the spot
rates at 31 January 2025.
Revenue is particularly exposed to
developments in USD and GBP relative to
DKK. Fluctuations in HUF against DKK
impact the operating profit because a
substantial part of our production, and
thus of our costs, are in Hungary, whereas
our sales there are moderate.
EFFECT OVER 12 MONTHS OF A 10% INITIAL
DROP IN EXCHANGE RATES FOR KEY
CURRENCIES (DKK MILLION)
Revenue
EBIT
USD
-740
-240
GBP
-370
-220
HUF
-
150
Announcement no. 01/2025 | 4 February 2025
15
Executive Management
Board of Directors
Announcement no. 01/2025 | 4 February 2025
16
Statement of comprehensive income
1 October – 31 December, unaudited
Consolidated
2024/25
2023/24
DKK million
Note
Q1
Q1
Index
Revenue
2
106
Production costs
-2,276
-2,102
108
Gross profit
105
Distribution costs
-2,329
-2,130
109
Administrative expenses
-295
-335
88
Research and development costs
-219
-233
94
Other operating income
62
Other operating expenses
-8
-5
160
Operating profit (EBIT) before special items
105
Special items
3
-74
-15
-
Operating profit (EBIT)
102
Financial income
4
>200
Financial expenses
4
-269
-335
80
Profit before tax
114
Tax on profit for the period
-725
-342
>200
Net profit for the period
86
Remeasurements of defined benefit plans
-7
-6
Tax on remeasurements of defined benefit plans
Items that will not be reclassified to the income statement
-6
-4
Value adjustment of currency hedging
-145
Recycle through the income statement
-53
Tax effect of hedging
Currency adjustment of opening balances and other value adjustments relating to subsidiaries
Items that may be reclassified to income statement
Total other comprehensive income
Total comprehensive income
DKK
Earnings per share (EPS)
Earnings per share (EPS), diluted
Announcement no. 01/2025 | 4 February 2025
17
Statement of cash flows
1 October – 31 December, unaudited
Consolidated
2024/25
2023/24
DKK million
Note
3 mths
3 mths
Operating profit
Amortisation
Depreciation
Adjustment for other non-cash operating items
6
-66
Changes in working capital
6
-112
Ingoing interest payments, etc.
Outgoing interest payments, etc.
-325
-146
Income tax paid
-60
-60
Cash flows from operating activities
Investments in intangible assets
-30
-40
Investments in land and buildings
-2
-1
Investments in plant and machinery and other fixtures and fittings, tools and equipment
-8
-8
Investments in property, plant and equipment under construction
-268
-227
Property, plant and equipment sold
Investment in other investments
-21
Company divestment
Cash flows from investing activities
-133
-267
Free cash flow
Dividend to shareholders
-3,831
-3,595
Sale of treasury shares and loss on exercised options
Financing from shareholders
-3,803
-3,494
Repayment of lease liabilities
-67
-62
Drawdown on credit facilities
Cash flows from financing activities
-1,761
-1,477
Net cash flows
Cash and cash equivalents at 1 October
Foreign exchange value adjustments
-35
Cash and cash equivalents, disposed operations
-4
Net cash flows
Cash and cash equivalents at 31 December
7
The cash flow statement cannot be derived using only the published financial data.
Announcement no. 01/2025 | 4 February 2025
18
Assets
At 31 December, unaudited
Consolidated
DKK million
Note
31.12.24
31.12.23
30.09.24
Intangible assets
Property, plant and equipment
Right-of-use assets
Other equity investments
Deferred tax asset
Other receivables
Non-current assets
Inventories
Trade receivables
Income tax
Other receivables
Prepayments
Cash and cash equivalents
Current assets
Assets
Announcement no. 01/2025 | 4 February 2025
19
Equity and liabilities
At 31 December, unaudited
Consolidated
DKK million
Note
31.12.24
31.12.23
30.09.24
Share capital
Currency translation reserve
-1,525
-1,443
-1,837
Reserve for currency hedging
Proposed ordinary dividend for the period
Retained earnings
Equity
Provisions for pensions and similar liabilities
Deferred tax liability
Other provisions
Bonds
5
Other credit institutions
Income tax
Other payables
Lease liability
Prepayments
Non-current liabilities
Provisions for pensions and similar liabilities
Other provisions
Bonds
5
Other credit institutions
Trade payables
Income tax
Other payables
Lease liability
Prepayments
Current liabilities
Equity and liabilities
Announcement no. 01/2025 | 4 February 2025
20
Statement of changes in equity, current year
At 31 December, unaudited
Consolidated
Share capital
Reserves
DKK million
A shares
B shares
Currency
translation
Currency
hedging
Proposed
dividend
Retained
earnings
Total
2024/25
Equity at 1 October
-1,837
Net profit for the period
Other comprehensive income
-89
Total comprehensive income
-89
Sale of treasury shares and loss on
exercised options
Share-based payment
Dividend paid out in respect of 2023/24
-3,831
-3,831
Transactions with shareholders
-3,831
-3,789
Equity at 31 December
-1,525
Announcement no. 01/2025 | 4 February 2025
21
Statement of changes in equity, last year
At 31 December, unaudited
Consolidated
Share capital
Reserves
DKK million
A shares
B shares
Currency
translation
Currency
hedging
Proposed
dividend
Retained
earnings
Total
2023/24
Equity at 1 October
-1,579
Net profit for the period
Other comprehensive income
-18
-33
Total comprehensive income
-18
Sale of treasury shares and loss on
exercised options
Share-based payment
Dividend paid out in respect of 2022/23
-3,595
-3,595
Transactions with shareholders
-3,595
-3,471
Equity at 31 December
-1,443
Announcement no. 01/2025 | 4 February 2025
22
Key accounting policies
1 Accounting policies
Profit and loss
2 Segment information
3 Special items
4 Financial income and expenses
Assets and liabilities
5 Bonds
Cash flows
6 Specifications of cash flow from operating activities
7 Cash and cash equivalents
Other disclosures
8 Contingent liabilities
List of notes
Announcement no. 01/2025 | 4 February 2025
23
Note 1
Accounting policies
The financial statements in this report is prepared in accordance with International Financial Reporting Standards as adopted by the
EU and additional Danish disclosure requirements for listed companies. The accounting policies for recognition and measurement
applied in the preparation of the financial statements in this report are consistent with those applied in the Annual Report 2023/24.
Note 2
Segment information
Operating segments
The operating segments are defined on the basis of the monthly reporting to the Executive Leadership Team, which is considered the
senior operational management and the management structure. Reporting to the Executive Leadership Team is based on five
operating segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, Advanced Wound Dressings and Biologics.
The segment Chronic Care covers the sale of ostomy care products and continence care products. The segment Voice and Respiratory
Care covers the sale of laryngectomy and tracheostomy products. The segment Interventional Urology covers the sale of urological
products, including disposable products. The segment Advanced Wound Dressings covers the sale of Advanced Wound Dressings, Skin
Care and Compeed contract manufacturing. The segment Biologics covers tissue-based products. The segmentation reflects the
structure of reporting to the Executive Leadership Team.
The shared/non-allocated costs comprises support functions (production units and staff functions) and eliminations, as these functions
do not generate revenue. While the costs of R&D for Interventional Urology, Voice and Respiratory Care and Biologics are included in
the segment operating profit/loss for the above-mentioned segments, R&D activities for Chronic Care and Advanced Wound Dressings
are shared functions which are included in shared/non-allocated functions. The shared/non-allocated costs also include PPA
amortisation expenditures related to Voice and Respiratory Care and Biologics. Financial items and income tax are not allocated to the
operating segments.
The Executive Leadership Team reviews each operating segment separately, applying their market contributions to earnings and
allocating resources on that basis. The market contribution is defined as external revenue less the sum of direct production costs,
distribution costs, sales costs, marketing costs and administrative expenses. Costs are allocated directly to segments. Certain
immaterial indirect costs are allocated systematically to the shared/non-allocated and the reporting segments.
The Executive Leadership Team does not receive reporting on assets and liabilities by the reporting segments. Accordingly, the
reporting segments are not measured in this respect, nor do we allocate resources on this background. No single customer accounts
for more than 10% of revenue.
Announcement no. 01/2025 | 4 February 2025
24
Note 2, continued
DKK million
Chronic Care
Voice and
Respiratory
Care
Interventional
Urology
Advanced
Wound
Dressings
Biologics
Group
2024/25
Segment revenue:
Ostomy Care
2,537
-
-
-
-
2,537
Continence Care
2,208
-
-
-
-
2,208
Voice and Respiratory Care
-
557
-
-
-
557
Interventional Urology
-
-
713
-
-
713
Advanced Wound Care
-
-
-
708
303
1,011
External revenue as per the
statement of comprehensive
income
4,745
557
713
708
303
7,026
Costs allocated to segment
-1,976
-361
-468
-450
-268
-3,523
Segment operating profit/loss
2,769
196
245
258
35
3,503
Shared/non-allocated
-1,591
Special items not included in segment operating profit/loss (see note 3)
-74
Operating profit before tax (EBIT) as per the statement of comprehensive income
1,838
Net financials
-69
Tax on profit/loss for the period
-725
Profit/loss for the period as per the statement of comprehensive income
1,044
DKK million
Chronic Care
Voice and
Respiratory
Care
Interventional
Urology
Advanced
Wound
Dressings
Biologics
Group
2023/24
Segment revenue:
Ostomy Care
2,382
-
-
-
-
2,382
Continence Care
2,067
-
-
-
-
2,067
Voice and Respiratory Care
-
508
-
-
-
508
Interventional Urology
-
-
703
-
-
703
Advanced Wound Care
-
-
-
717
229
946
External revenue as per the
statement of comprehensive
income
4,449
508
703
717
229
6,606
Costs allocated to segment
-1,857
-338
-462
-458
-206
-3,321
Segment operating profit/loss
2,592
170
241
259
23
3,285
Shared/non-allocated
-1,463
Special items not included in segment operating profit/loss (see note 3)
-15
Operating profit before tax (EBIT) as per the statement of comprehensive income
1,807
Net financials
-253
Tax on profit/loss for the period
-342
Profit/loss for the period as per the statement of comprehensive income
1,212
Announcement no. 01/2025 | 4 February 2025
25
Note 3
Special items
DKK million
2024/25
2023/24
Integration activities
18
15
Profitability improvement initiatives in Advanced Wound Care incl. Skin Care divestment
30
-
Management restructuring
26
-
Total
74
15
In the financial year 2024/25 special items contain expenses related to integration costs for the Atos Medical and Kerecis acquisitions.
Special items also include costs related to the margin improvement initiatives in Advanced Wound Care, including the divestment of
the Skin Care business, as well as Management restructuring costs.
Last year special items contain expenses related to integration costs for the Atos Medical acquisition.
Note 4
Financial income and expenses
DKK million
2024/25
2023/24
Financial income
Interest income
33
22
Fair value adjustments of forward contracts transferred from other comprehensive income
-
34
Fair value adjustments of cash-based share options
1
1
Interest hedges
19
19
Net exchange adjustments
142
-
Hyperinflationary adjustment of net monetary position
3
6
Other financial income
2
-
Total
200
82
Financial expenses
Interest expenses
121
39
Interest expenses, lease liabilities
9
6
Interest expenses, bonds
74
129
Fair value adjustments of forward contracts transferred from other comprehensive income
49
-
Net exchange adjustments
-
139
Other financial expenses and fees
16
22
Total
269
335
Announcement no. 01/2025 | 4 February 2025
26
Note 5
Bonds
Bonds
Coloplast has outstanding senior unsecured notes in an aggregate principal amount of EUR 1.5 billion under the Coloplast Euro
Medium Term Note programme. The Notes are unconditionally and irrevocably guaranteed by Coloplast. COLOCB2 and COLOCB3
carries a fixed coupon until expiry date.
COLOCB2 and COLOCB3 can be redeemed at a market price fixed on the redemption date in relation to named EUR bonds with similar
maturity.
A pre-hedge was made in 2021/22 with Interest swaps on COLOCB2 and COLOCB3 with mandatory breakage on the day the bonds are
issued to limit the financial risks. The gain of DKK 521 million has as per hedge accounting been set off in the equity and transferred to
the financial items during the lifetime of the bonds.
Short name
Currency
Amount,
million
Expiry date
Coupon
COLOCB2
EUR
850
19-05-2027
2.25
COLOCB3
EUR
700
19-05-2030
2.75
Note 6
Specifications of cash flow from operating activities
DKK million
2024/25
2023/24
Change in other provisions
4
-87
Other non-cash operating items
15
21
Adjustment for other non-cash operating items
19
-66
Inventories
-8
-63
Trade receivables
116
-169
Other receivables, including amounts held in escrow
68
-77
Trade and other payables etc.
-4
197
Changes in working capital
172
-112
Announcement no. 01/2025 | 4 February 2025
27
Note 7
Cash and cash equivalents
DKK million
2024
2023
Bank deposits, short term
906
916
Cash and cash equivalents at 31 December
906
916
Note 8
Contingent liabilities
The Coloplast Group is a party to a few minor legal proceedings, which are not expected to influence the Group’s future earnings.
Announcement no. 01/2025 | 4 February 2025
28
Income statement, quarterly
Unaudited
Consolidated
2024/25
2023/24
DKK million
Q1
Q4
Q3
Q2
Q1
Revenue
7,026
6,953
6,885
6,586
6,606
Production costs
-2,276
-2,313
-2,237
-2,109
-2,102
Gross profit
4,750
4,640
4,648
4,477
4,504
Distribution costs
-2,329
-2,292
-2,251
-2,152
-2,130
Administrative expenses
-295
-285
-300
-324
-335
Research and development costs
-219
-219
-240
-221
-233
Other operating income
13
19
17
18
21
Other operating expenses
-8
-60
-4
-7
-5
Operating profit (EBIT) before special items
1,912
1,803
1,870
1,791
1,822
Special items
-74
104
-36
-19
-15
Operating profit (EBIT)
1,838
1,907
1,834
1,772
1,807
Financial income
200
23
34
36
82
Financial expenses
-269
-327
-237
-201
-335
Profit before tax
1,769
1,603
1,631
1,607
1,554
Tax on profit for the period
-725
-289
-357
-355
-342
Net profit for the period
1,044
1,314
1,274
1,252
1,212
DKK
Earnings per share (EPS) before special items
4.89
5.47
5.79
5.63
5.45
Earnings per share (EPS)
4.63
5.84
5.66
5.57
5.39
Earnings per share (EPS) before special items, diluted
4.89
5.47
5.79
5.63
5.45
Earnings per share (EPS), diluted
4.63
5.84
5.66
5.57
5.39
Announcement no. 01/2025 | 4 February 2025
29
Our mission
Making life easier for people
with intimate health care needs
Our values
Closeness... to better understand
Passion... to make a difference
Respect and responsibility... to guide us
Our vision
Setting the global standard
for listening and responding
For further information, please contact
Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111
Aleksandra Dimovska
Vice President, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: [email protected]
Simone Dyrby Helvind
Senior Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 2981
Email: dksdk@coloplast.com
Press and media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: [email protected]
Address
Company reg. (CVR) no. 69749917
Website
www.coloplast.com
This announcement is available in a Danish and an English-language version. In the event of discrepancies,
the English version shall prevail.
Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the
skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over
decades, we have helped millions of people to live a more independent life and we continue to do so through innovative
products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care,
The Coloplast logo is a registered
trademark of Coloplast A/S
©
2025-
02
All rights reserved Coloplast A/S,
3050 Humlebaek, Denmark.